


The Board of Directors
RPG Life Sciences Limited
RPG House
463, Dr. Annie Besant Road
Worli, Mumbai - 400 030

1. We have reviewed the results of RPG Life Sciences Limited (the 'company') for the quarter ended 30th June, 2012 which are included in the accompanying 'Statement of Standalone Unaudited Results for the quarter ended 30th June, 2012' (the 'Statement'), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. The Statement has been prepared by the company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" Issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration No. 301056E
Chartered Accountants


Himanshu Goradia
Partner
Membership No. 45668

Mumbai, 9th August, 2012

RPG LIFE SCIENCES LIMITED

25, M.I.D.C Land, Thane - Belapur Road, Navi Mumbai 400 705, India.
Phones : 6785 5400 / 5555 / 5399 / 5398. Fax : 2767 2646 / 2763 1062

PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2012 (Rs. in lakhs)				
Particulars	3 months ended 30.6.2012	3 months ended 31.3.2012	3 months ended 30.6.2011	Year ended 31.3.2012
	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,472	4,123	5,052	18,923
(b) Other Operating Income	107	97	72	359
Total Income from Operations	5,579	4,220	5,124	19,282
2. Expenses				
(a) Cost of Materials Consumed	1,355	931	1,250	4,465
(b) Purchases of Stock-in-Trade	359	354	294	1,195
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	140	194	(226)	(140)
(d) Employee Benefits Expense	1,227	1,224	1,126	4,999
(e) Depreciation and Amortisation Expense	237	260	248	1,022
(f) Other Expenses	1,850	1,782	1,744	6,948
Total Expenses	5,168	4,745	4,436	18,489
3. Profit/(Loss) from Operations before Other Income and Finance Costs	411	(525)	688	793
4. Other Income	42	12	10	69
5. Profit/(Loss) from Ordinary Activities before Finance Costs	453	(513)	698	862
6. Finance Costs	168	130	134	688
7. Profit/(Loss) from Ordinary Activities before Tax	285	(643)	564	174
8. Tax Expense/(Credit) (Including Deferred Tax)	6	(74)	163	89
9. Net Profit/(Loss) for the period	279	(569)	401	85
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				6,091
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):				
(a) Basic	1.69	(3.44)	2.43	0.51
(b) Diluted	1.69	(3.44)	2.42	0.51

PART II Select Information for the Quarter ended 30th June, 2012				
Particulars	3 months ended 30.6.2012	3 months ended 31.3.2012	3 months ended 30.6.2011	Year ended 31.3.2012
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	7,754,293	7,754,293	7,934,286	7,754,293
- Percentage of Shareholding	46.90	46.90	47.98	46.90
2. Promoters and Promoter Group Shareholding				
(a) Pledged/Encumbered				
- Number of Shares	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
(b) Non-Encumbered				
- Number of Shares	8,780,948	8,780,948	8,600,955	8,780,948
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the company)	53.10	53.10	52.02	53.10

Regd. off.: RPG House, 483, Dr. Annie Besant Road, Worli, Mumbai 400 030. Phone : 2498 1650 / 1651, 6660 6375 to 6378, Fax : 2497 0127, 6660 4715



RPG LIFE SCIENCES LIMITED

25, M.I.D.C Land, Thane - Belapur Road, Navi Mumbai 400 705, India.


Phones : 6795 5400 / 5555 / 5399 / 5398, Fax : 2767 2646 / 2763 1052



Particulars	3 months ended 30.6.2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	13
Disposed of during the quarter	13
Remaining unsolved at the end of the quarter	-

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 9th August, 2012.
2. The results for the quarter ended 30th June, 2012 have been subjected to limited review by the statutory auditors of the company.
3. The company is exclusively engaged in pharmaceuticals segment.
4. The company continues to invest strongly in building of brands to gain market share.
5. The company continues to actively focus on the remedial measures towards regaining EU GMP certification in the ensuing inspection by the Ministry of Social and Family Affairs, Health and Consumer Protection, Hamburg, Germany for the company's API facility at Navi Mumbai, Maharashtra which was not granted certification in December 2011, citing certain deficiencies. Consequently, some of the orders were cancelled for the quarter ended 31st March, 2012 adversely affecting the business of the company.
6. The figures for the quarter ended 31st March, 2012 are the balancing figures between the audited financial results for the year ended 31st March, 2012 and the published unaudited financial results for the nine months ended 31st December, 2011.
7. Figures for the prior periods have been regrouped where necessary.



For RPG Life Sciences Limited

Ajit Singh Chouhan
Managing Director
Mumbai, 9th August, 2012

Regd. off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030, Phone : 2498 1650 / 1651, 8660 6375 to 6378, Fax : 2497 0127, 8660 4715

